Clinical Trials on Adenocarcinoma Gastric

Total 12214 results

Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Liangjun Zhu M.M.
Zhangjiagang First People's Hospital

Recruiting

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Metastatic or Recurrent Gastric Adenocarcinoma

China
China Medical University, China

Unknown

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Metastatic Gastric Adenocarcinoma

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Unknown

Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer (HIPEC)

Advanced Gastric Adenocarcinoma

China
Mayo Clinic

Recruiting

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
Mebiopharm Co., Ltd

Unknown

Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Georgia
Seagen Inc.

Active, not recruiting

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
Thomas Jefferson University
National Cancer Institute (NCI)

Completed

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Adenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal Cancer

United States
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Artiva Biotherapeutics, Inc.

Not yet recruiting

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Peking University

Recruiting

Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach

Gastric Cancer

China
RenJi Hospital

Not yet recruiting

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric Cancer
The First Affiliated Hospital of Anhui Medical...

Recruiting

Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection (CAPOGA)

Gastric Cancer

China
Sander van Hootegem

Completed

The Diagnostic Value of Staging Laparoscopy and Computed Tomography Response Assessment in Patients With Gastric Adenocarcinoma

Gastric Cancer

Netherlands
National University Hospital, Singapore

Unknown

The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma

Gastric Cancer

Singapore
Yonsei University

Completed

Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma

Gastric Cancer

Korea, Republic of
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditions

United States
AstraZeneca

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Spain, China, Korea, Republic of, United States, Taiwan, Japan, United Kingdom
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

Gastric Cancer

United States, Australia, Belgium, Korea, Republic of, Russian Federation, Germany, Poland, Spain, Argentina, Austria, Brazil, Bulgaria, Chile, Estonia, France, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Sing... and more
Sanofi

Completed

Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma

Gastric Cancer

Korea, Republic of
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Johannes Gutenberg University Mainz
Pfizer

Completed

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

Gastric Adenocarcinoma | Barrett Esophagus

Germany
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Accelerated Community Oncology Research Network
Amgen

Terminated

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal Stomach

United States
National Cancer Institute (NCI)

Recruiting

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

Stomach Neoplasms | Stomach Cancer | Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) | Hereditary Diffuse Gastric Cancer (HDGC) | Familial Diffuse Gastric Cancer

United States
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
Samsung Medical Center

Not yet recruiting

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Gastric Cancer
Cancer Institute and Hospital, Chinese Academy...

Completed

Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

Gastric Cancer

China
Henan Cancer Hospital

Active, not recruiting

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Henan Cancer Hospital

Active, not recruiting

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Gastric Cancer

China
First Affiliated Hospital of Zhejiang University

Unknown

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Gastric Cancer

China
University of Southern California

Completed

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Adenocarcinoma | Gastric Cancer

United States
Milad Hospital

Completed

Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma (TOX)

Gastric Cancer

Iran, Islamic Republic of
Spanish Cooperative Group for the Treatment of...
Sanofi; Hoffmann-La Roche

Completed

Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status

Gastric Cancer

Spain
Royal Marsden NHS Foundation Trust
AstraZeneca

Unknown

A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer (SOLAR)

Gastric Cancer | Oesophageal Cancer | Gastro-Oesophageal Junction Cancer

United Kingdom
Laval University
Ciusss de L'Est de l'Île de Montréal

Terminated

Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

Gastric Cancer | Gastric Adenocarcinoma | Peritoneal Carcinomatosis | Peritoneal Metastases

Canada
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan
Novartis Pharmaceuticals

Completed

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Advanced Gastric Cancer | Gastro-esophageal Junction Cancer

United States, France, Italy, Taiwan, United Kingdom, Turkey, Germany, Singapore, Australia, Russian Federation, Korea, Republic of, Switzerland, Netherlands, Canada
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Shanghai Zhongshan Hospital

Recruiting

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Advanced Gastric Cancer

China
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Clinical Trials on Adenocarcinoma Gastric

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations